Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.

Giornale Italiano di Cardiologia is a premier journal in the field of cardiology, published by PENSIERO SCIENTIFICO EDITORE. Established in 1996, this journal serves as an essential platform for sharing the latest research and clinical advancements in cardiovascular medicine, particularly catering to the Italian and international medical communities. Although currently classified in the Q4 quartile for Cardiology and Cardiovascular Medicine (2023), the journal strives to enhance its impact and outreach by embracing rigorous peer-review practices and promoting high-quality submissions. With a commitment to enriching knowledge and fostering dialogue among researchers, clinicians, and students, the journal offers a collection of articles that include original research, reviews, and case studies. While currently not an Open Access publication, readers will benefit from a wealth of research insights that contribute to advancements in cardiac care and treatment strategies. As the Giornale Italiano di Cardiologia continues to evolve, it plays a vital role in bridging research and clinical practice in the cardiovascular domain.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Indian Heart Journal, published by Elsevier, is a distinguished peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. Founded in 1961, this journal has been a pivotal resource for researchers, healthcare professionals, and students, providing a platform for innovative studies and insights into heart health. The journal transitioned to an Open Access model in 2013, ensuring widespread dissemination of vital research findings to enhance global understanding of cardiovascular diseases. Ranked in the Q3 category for Cardiology and Cardiovascular Medicine in 2023, it holds a reputable position in the medical community, with a Scopus rank of #222 out of 387 journals in the same field, placing it in the 42nd percentile. The Indian Heart Journal strives to foster advances in clinical practice and research while addressing the unique cardiac health challenges faced in India and beyond.

International Journal of Cardiology Cardiovascular Risk and Prevention is a distinguished Open Access journal published by ELSEVIER, dedicated to advancing research in the realms of cardiology and cardiovascular medicine. With an ISSN of 2772-4875 and based in the Netherlands, this journal has rapidly established itself as a critical resource for academics and practitioners since its inception in 2021. The journal currently holds a respectable impact factor and occupies the Q2 quartile in both Cardiology and Cardiovascular Medicine and Internal Medicine categories, reflecting its commitment to sharing high-quality research. Researchers can take advantage of its open-access model, ensuring that cutting-edge findings are freely available to a global audience. The journal not only covers innovative studies on cardiovascular risk factors and prevention strategies but also aims to facilitate interdisciplinary collaboration. With an ongoing trajectory from 2021 to 2024, the International Journal of Cardiology Cardiovascular Risk and Prevention is poised to remain a pivotal platform for dialogue and discovery in the evolving landscape of cardiovascular health.

Clinical and Experimental Hypertension, published by Taylor & Francis Inc, is a crucial resource in the fields of internal medicine and physiology. With its inaugural publication dating back to 1978, this esteemed journal has successfully merged decades of research, providing a platform for the latest advancements in hypertension studies. Operating without an open access model, it is configured to serve a specialized audience of researchers, clinicians, and students who are dedicated to exploring innovative treatment modalities and understanding the complexities of hypertensive diseases. Ranked in the Q3 category in both Internal Medicine and Physiology, this journal accomplishes a commendable standing in the academic community, exemplified by its Scopus rankings which position it within the median percentile range in its field. By disseminating high-quality research and fostering scientific dialogue, Clinical and Experimental Hypertension plays a pivotal role in shaping contemporary understanding and clinical practices concerning hypertension management.

American Journal of Preventive Cardiology, published by ELSEVIER, is a premier Open Access journal that has been making significant strides in the field of cardiology since its inception in 2020. With an impressive impact factor and recognized as a Q1 journal in the Cardiology and Cardiovascular Medicine category as of 2023, it ranks 77th out of 387 in the Scopus database, placing it in the 80th percentile of its field. The journal aims to promote the latest research and practices in preventive cardiology, addressing the global burden of cardiovascular diseases through a combination of innovative findings and practical applications. With the advantage of Open Access, all published articles are readily available to researchers, professionals, and students worldwide, fostering a broad dissemination of knowledge and encouraging collaboration across disciplines. Based in Amsterdam, Netherlands, the journal is committed to advancing the science and prevention of heart disease, making it an essential resource for those dedicated to improving cardiovascular health.